[1]
Bodor, N.; Prokai, L.; Wu, W.; Farag, H.; Jonnalagadda, S.; Kawamura, M.; Simpkins, J. A Strategy for Delivering Peptides into the Central Nervous System by Sequential Metabolism. Science, 1992, 257(5077), 1698-1700.
[2]
Bodor, N.; Buchwald, P. A Molecular Size Based Approach to Estimate Partition Properties for Organic Solutes. J. Phys. Chem. B, 1997, 101, 3404-3412.
[http://dx.doi.org/10.1021/jp9638503]
[http://dx.doi.org/10.1021/jp9638503]
[3]
Bodor, N.; Buchwald, P. Soft Drug Design: General Principles and Recent Applications. Med. Res. Rev., 2000, 20, 58-101.
[4]
Bodor, N.; Tóth-Sarudy, È.; Holm, T.; Pallagi, I.; Vass, E.; Buchwald, P.; Langel, Ü. Novel Cell-Penetrating Molecular Transporters with Flexible Backbones and Permanently Charged Side Chains. J. Pharm. Pharmacol., 2007, 8, 1065-1076.
[5]
Bodor, N.; Buchwald, P. Retrometabolic drug design: Principles and recent developments. Pure and Applied Chemistry. IUPAC, 2008, 80(8), 1669-1682.
[6]
Buchwald, P.; Bodor, N. Brain-Targeting Chemical Delivery Systems and Their Cyclodextrin-Based Formulations in Light of the Contributions of Marcus E. Brewster. J. Pharm. Sci., 2016, 105, 2589-2600.
[http://dx.doi.org/10.1016/j.xphs.2016.04.007]
[http://dx.doi.org/10.1016/j.xphs.2016.04.007]
[7]
Bodor, E.T.; Wu, W-M.; Chandran, R.; Bodor, N. Enhanced Activity of Topical Hydrocortisone by Competitive Binding of Corticosteroid-Binding Globulin. J. Pharm. Sci., 2016, 105, 2873-2878.
[http://dx.doi.org/10.1016/j.xphs.2016.03.028]
[http://dx.doi.org/10.1016/j.xphs.2016.03.028]
[8]
Bodor, N.; Zubovics, Z.; Kurucz, I.; Sólyom, S.; Bodor, E.T. Potent Analogs of Etiprednol Dicloacetate, a Second Generation of Soft Corticosteroids. J. Pharm. Pharmacol., 2017, 69(12), 1745-1753.
[http://dx.doi.org/10.1111/jphp.12819]
[http://dx.doi.org/10.1111/jphp.12819]
[9]
Bodor, N.; Bodor, E.T. The First 40 Years of Soft Anticholinergic Agents. Rev. Roum. Chim., 2021, 66(2), 125-133.
[http://dx.doi.org/10.33224/rrch.2021.66.2.03]
[http://dx.doi.org/10.33224/rrch.2021.66.2.03]
[10]
Murakami, T.; Bodor, E.T.; Bodor, N. Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs. Expert Opin. Drug Metab. Toxicol., 2021, 17(5), 555-580.
[http://dx.doi.org/10.1080/17425255.2021.1902986]
[http://dx.doi.org/10.1080/17425255.2021.1902986]
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
